14 / 38
RADIANT – 1 Pancreatic NET
Everolimus +/- Octreotide
ORR=9.6% + PFS = 9.7 m
ORR=4.4% + PFS = 16.7 m
RADIANT - 2 Advanced NET
Funcioning/Non-functioning
Octreotide LAR + Everolimus
Octreotide LAR + Placebo
mPFS = 16.4 vs 11.3 m;
HR0.77; p=0.026 (one sided)
RADIANT - 3 Pancreatic NET
Everolimus (% pts with SSA)
Placebo
mPFS = 11 vs 4.6 m;
HR 0.35; p<0.001
RADIANT - 4 Non functioning
-
Lung
-
GI
Everolimus
Placebo
mPFS = 11 vs 3.9 m;
HR 0.48; p<0.00001
EVEROLIMUS
TARGETED AGENTS
Yao JC, et al. J Clin Oncol. 2010;28:69–76
Pavel ME, et al. Lancet. 2011;378:2005-2012
Yao JC, et al. N Engl J Med 2011; 364:514-523
Yao JC, et al. Lancet 2016; 387: 968–77
N= 1141 patients in phase III RCT